Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ArQule -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (197)	4/2/1998 1:15:00 AM
From: William Nelson	Respond to of 399

This is interesting...I hadn't really thought about arql growing into a regular pharma. I have to doubt they can develop much of a pipeline of their own without stepping on the toes of their partners...or getting sued by them. If I try to picture these guys future (admittedly prematurely...), I see them combining with one or more other biotechs like hgsi or mlnm, resulting in a factory for finding and patenting lead molecules. Then others can develop them and arql++ can sit back and rake in royalties. Or maybe the patent lifetime isn't long enough to make this a good business?? BTW, I had no idea arql gets 50/50 on these deals. This makes me much more optimistic...although I can't believe biotechs are giving this kind of cut on their best stuff. Maybe they try arql for leads that seem shakier.